Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(22):1711-1717; doi:10.1093/jnci/djg099
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sidransky, D.
Right arrow Articles by Mao, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sidransky, D.
Right arrow Articles by Mao, L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

ARTICLE

Serum Protein MALDI Profiling to Distinguish Upper Aerodigestive Tract Cancer Patients From Control Subjects

David Sidransky, Rafael Irizarry, Joseph A. Califano, Xianbin Li, Hening Ren, Nicole Benoit, Li Mao

Affiliations of authors: Department of Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Research Division, The Johns Hopkins University School of Medicine, Baltimore, MD (DS, JAC, NB); Department of Biostatistics, The Johns Hopkins University Bloomberg School of Public Health, Baltimore (RI, XL); Department of Thoracic/Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston (HR, LM).

Correspondence to: David Sidransky, MD, Head and Neck Cancer Research, The Johns Hopkins University School of Medicine, 818 Ross Research Bldg., 720 Rutland Ave., Baltimore, MD 21205-2196 (e-mail: dsidrans{at}jhmi.edi) or Rafael Irizarry, Department of Biostatistics, The Johns Hopkins University, Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD 21205-2179 (e-mail: rafa{at}jhu.edu)

Background: There are no reliable blood markers for the early detection and monitoring of aerodigestive tract tumors. Recent studies have suggested that serum protein patterns may be able to distinguish cancer patients from control subjects. Methods: We used matrix-assisted laser desorption and ionization (MALDI) mass spectroscopy to obtain serum protein patterns from patients with head and neck cancer (n = 99) or lung cancer (n = 92) and from control subjects (n = 143) at risk for the development of these cancers. From the mass spectra, we predicted the cancer status of patients using a simple classification procedure based on a t test feature selection and linear discriminant analysis (LDA). We cross-validated the data with 200 random data simulations to establish a range of the LDA tuning parameter, which was used to construct receiver operating characteristic (ROC) curves. Results: Average total protein levels were higher in case patients than in control subjects, although the differences were not statistically significant. Ten individual m/z peaks, from 5 to 111 kd, appeared frequently in head and neck cancer patients but not in control subjects. Using the 45 top predictors, selected by spectral mass and LDA, we observed that ROC curves differed from those expected under the null hypothesis, suggesting that spectral profiles from the sera of patients with head and neck cancer statistically significantly differed from the sera of control subjects. The model developed on head and neck cancer patients could also be used to identify patients with lung cancer. Conclusions: The pattern of protein spectra in total serum reliably distinguished cancer case patients from control subjects. Incorporation of MALDI assays into prospective longitudinal trials to assess the true predictive values of protein spectra in cancer detection is needed.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
JNCI J Natl Cancer InstHome page
K. Yanagisawa, S. Tomida, Y. Shimada, Y. Yatabe, T. Mitsudomi, and T. Takahashi
A 25-Signal Proteomic Signature and Outcome for Patients With Resected Non-Small-Cell Lung Cancer
J Natl Cancer Inst, June 6, 2007; 99(11): 858 - 867.
[Abstract] [Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
C. G. Gourin, Z.-S. Xia, Y. Han, A. M. French, A. K. O'Rourke, D. J. Terris, and B.-L. Adam
Serum protein profile analysis in patients with head and neck squamous cell carcinoma.
Arch Otolaryngol Head Neck Surg, April 1, 2006; 132(4): 390 - 397.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
M. W. Duncan and S. W. Hunsucker
Proteomics as a Tool for Clinically Relevant Biomarker Discovery and Validation
Experimental Biology and Medicine, December 1, 2005; 230(11): 808 - 817.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. G. Soltys, Q.-T. Le, G. Shi, R. Tibshirani, A. J. Giaccia, and A. C. Koong
The Use of Plasma Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Proteomic Patterns for Detection of Head and Neck Squamous Cell Cancers
Clin. Cancer Res., July 15, 2004; 10(14): 4806 - 4812.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.